Angiotensin (Ang) II has an important role in the vascular smooth muscle cell (VSMC) proliferation and migration and subsequently in the development of vascular diseases, whereas dopamine has the opposite effect. Previous studies have shown an interaction between dopamine and AT 1 receptors in the kidney. The dopamine D 4 receptor is expressed in arteries and has an inhibitory effect on VSMC proliferation. We hypothesized that the D 4 receptor, through its interaction with the AT 1a receptor, may have an inhibitory effect on Ang II-mediated VSMC proliferation and migration, which could have a pivotal role in hypertensioninduced vascular remodeling. In the current study, we found that Ang II markedly induced the proliferation and migration of A10 cells, which was inhibited by the D 4 receptor agonist PD168077. The activation of the D 4 receptor by PD168077 inhibited AT 1a receptor expression in a concentration-and time-dependent manner. These effects were attenuated by silencing the D 4 receptor with a D 4 receptor-targeting small interfering RNA. The D 4 receptor-mediated inhibition of AT 1 receptor function involved protein kinase A (PKA). The activation of the D 4 receptor by PD168077 increased PKA activity in A10 cells, and the presence of a PKA inhibitor (PKA inhibitor 14-22, 10 − 7 mol l − 1 per 24 h) blocked the inhibitory effect of the D 4 receptor on AT 1 receptor expression and function. The inhibitory effect of the D 4 receptor on AT 1 receptor expression and function was preserved in VSMCs (primary culture) from spontaneously hypertensive rats relative to VSMCs from Wistar-Kyoto rats. In conclusion, our data provide insight into the regulatory role of the D 4 receptor on AT 1a receptor expression and function in VSMCs and suggest that targeting the action of the D 4 receptor may represent an effective therapeutic approach for the treatment of cardiovascular diseases.
INTRODUCTION
Vascular smooth muscle cells (VSMCs) are critically involved in vascular diseases. The abnormal proliferation and migration of VSMCs participate in smooth muscle hypertrophy, which is often associated with many vascular diseases, including hypertension, atherosclerosis and restenosis after balloon angioplasty. 1,2 Angiotensin II (Ang II), as the major effector of the renin-angiotensin system, has an important role in regulating blood pressure and body fluid volume. Moreover, Ang II, via the AT 1a receptor, is a critical regulator of rat VSMC proliferation and migration, which are essential in the vascular remodeling associated with hypertension. [3] [4] [5] [6] Dopamine receptors exert their beneficial effects on blood pressure homeostasis through the regulation of epithelial sodium transport and vascular smooth muscle tone. Dopamine receptors are classified into the D 1 -like and D 2 -like subtypes based on their structure and pharmacology. D 1 -like receptors are composed of D 1 and D 5 receptors, whereas D 2 -like receptors are composed of D 2 , D 3 and D 4 receptors. [7] [8] [9] [10] [11] As a major component of the D 2 -like receptor subfamily, the D 4 receptor has been shown to have an important role in the pathogenesis of hypertension. D 4 receptor-deficient mice have higher blood pressure than wild-type mice. 9, 12 There is increasing evidence of an interaction between dopamine receptors and the AT 1 receptor. [12] [13] [14] [15] Our previous study showed a negative interaction between D 3 and AT 1 receptors whereby the activation of the D 3 receptor inhibits AT 1 receptor expression and function in renal proximal tubule cells. 15 The disruption of the D 4 dopamine receptor gene in mice produces hypertension that is associated with increased renal AT 1 receptor expression. The hypotensive effect of a bolus intravenous injection of the AT 1 receptor antagonist losartan lasted longer in D 4 receptor-deficient mice than their wild-type littermates. 12 The D 4 receptor is expressed in VSMCs and activation of the D 4 receptor inhibits insulin-mediated VSMC proliferation and migration. 16 We hypothesized that the D 4 receptor, by interacting with the AT 1a receptor, may have an inhibitory effect on Ang II-mediated VSMC proliferation and migration and could therefore play a pivotal role in hypertension-induced vascular remodeling. To test this hypothesis, we used immortalized rat aortic smooth muscle cells (A10) and primary cultures of aortic VSMCs from Wistar-Kyoto (WKY) and spontaneously hypertensive rats (SHRs) to determine whether the D 4 receptor affects Ang II-induced proliferation and migration of VSMCs and investigated possible signaling pathways of such an interaction.
METHODS Materials
PD168077, L745870 (a dopamine D 4 receptor antagonist) and Ang II were purchased from Sigma (Sigma, St Louis, MO, USA). Rabbit polyclonal AT 1 receptor antibody and monoclonal α-actin antibody were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). PKA inhibitor 14-22 was purchased from Calbiochem (Darmstadt, Germany). SDS-polyacrylamide gels were from Pierce (Rockford, IL, USA). Polyvinylidene fluoride (PVDF) and protein gel apparatus were purchased from Bio-Rad (Hercules, CA, USA). Minimal essential medium (MEM), Dulbecco's modified Eagle's medium (DMEM) and fetal bovine serum (FBS) were obtained from Gibco/Invitrogen (Carlsbad, CA, USA); fibroblast growth factor (FGF), epidermal growth factor (EGF), phosphate-buffered saline (PBS), penicillin/streptomycin and nonessential amino acids were purchased from Sigma.
Cell culture
A10 cells, 16, 17 a smooth muscle cell line from rat thoracic aorta, were purchased from ATCC (A10; ATCC, Hercules, CA, USA). Primary VSMCs were isolated from the aortae of 8-week-old male (200-220 g) SHRs and age-matched WKY rats (Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences, Beijing, China) using a digestion method. 18, 19 VSMCs were grown in 10% FBS-DMEM containing 1% antibiotics and incubated in a CO 2 incubator (95% CO 2 , 37°C). After reaching 70% confluence, the VSMCs were incubated in serum-free DMEM for 16-24 h prior to use.
VSMC proliferation assay
VSMC proliferation was quantified by measuring the uptake of tetrazolium salt, 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) and using cell counting assays. The cells were seeded into 96-well (100 μl of medium per well) culture plates at a density of 1 × 10 4 cells per well, made quiescent for 24 h and then pretreated with PD168077 with or without L745870 for 30 min, followed by stimulated with various concentrations of Ang II for an additional 24 h. Subsequently, 20 μl of MTT (5 mg ml − 1 ) were added to each well, and the incubation was continued for an additional 4 h at 37°C. Next, dimethyl sulfoxide (DMSO, 150 μl) was added to each well, and absorbance was read at 490 nm on a microplate reader (model 680, Bio-Rad). The growth of the VSMCs was examined by cell counting. The cells were made quiescent by serum starvation in serum-free medium, then pretreated with PD168077 with or without L745870 for 30 min and stimulated with Ang II for an additional 24 h. After incubation, the cells were counted in a hemocytometer (trypan blue uptake, which indicates cell death, was observed in o10% of the cells). Each count is an average of three repeat samplings, and each data point is the average of three experiments. 16, 17 
VSMC migration
Cell migration was examined using transwell and scratch-wound migration assays. 16, 20 The transwell migration assay was performed using 24-well tissue culture plates (BD Bioscience, Becton, NJ, USA) with an 8-μm-pore polycarbonate membrane. The number of migratory cells was counted in 10 randomly chosen fields of duplicate chambers at a magnification of × 200 for each sample. For the scratch-wound migration assay, VSMCs were seeded in a six-well plate at a density of 1 × 10 5 cells per well, grown to confluence, starved for 24 h and then pretreated with PD168077 with or without L745870 for 30 min and stimulated with Ang II for an additional 24 h. The cell monolayer was scratched with a small tip along the ruler and allowed to recover for 24 h in fresh starvation medium (serum-free DMEM) for 48 h. The cells were visualized using an Olympus IX-70 inverted microscope (Olympus, Tokyo, Japan). The migration area (%) was analyzed in 10 randomly chosen fields under an inverted microscope by using NIH Image J software, area at 0 h pre area at 48 h × 100% was calculated.
Immunoblotting A10 cells were treated with vehicle (dH 2 O), PD168077 or L745870 at the indicated concentrations and times. After treatment, the A10 cells were washed once in PBS and lysed in a lysis buffer. Extraction of proteins, electrophoresis, transfer, immunodetection and densitometric evaluation were performed as previously described. [15] [16] [17] 21 The amount of protein transferred onto the membranes was normalized by immunoblotting with α-actin (1:400).
Transfection with D 4 receptor-targeting siRNA
Knockdown of the D 4 receptor with siRNA was accomplished in A10 cells by transfection with 2.5 -μl D 4 receptor-targeting siRNA or scrambled siRNA (scRNA) for 48 h, using Lipofectamine 2000 reagent (Invitrogen). 22, 23 After transfection, quiescent VSMCs were pretreated with PD168077 for 30 min and then stimulated with Ang II for an additional 24 h prior to immunoblotting, proliferation and migration assays. 16, 17, 20 RT-PCR and real-time quantitative PCR Total RNA from A10 cells was isolated using a Trizol procedure (Invitrogen). Total RNA (2 μg) was used to synthesize the cDNA, which served as a template for the amplification of AT 1a receptor and β-actin (housekeeping gene). Primer sequences for AT 1a receptor were 5′-AAAGGGCAAGGAACCTTTGT-3′ (forward) and 5′-CAGATGCGAAATAACGCAGA-3′ (reverse). Primer sequences for β-actin were 5′-GTGGGTATGGGTCAGAAGGA-3′ (forward) and 5′-AGCGCGTAACCCT CATAGAT-3′ (reverse). The amplification was performed under the following conditions: 94°C for 2 min, followed by 35 cycles of denaturation at 94°C for 30 s, annealing at 58°C for 30 s and extension at 72°C for 45 s. This was followed by a final extension at 72°C for 10 min. The PCR products were electrophoresed in 2% agarose gels. 16, 17 AT 1a mRNA was quantified by real-time quantitative (q) RT-PCR using SYBR green PCR technology (Applied Biosystems, Foster City, CA, USA) with the following conditions: 10 s at 95°C; 45 s at 62°C; 60 s at 72°C, repeated for 40 cycles. 23, 24 Each qRT-PCR sample was normalized by the expression of ribosomal protein S16 and is expressed as fold change. Primer sequences of AT 1a receptor and 16S used for qRT-PCR are follows: AT 1a receptor forward 5′-GCGGTCTCCT TTTGATTTCC-3′, reverse 5′-CAAAGGGCTCCTGAAACTTG-3′ (reverse). 16S forward 5′-ATCTCAAAGGCCCTGGTAGC-3′, reverse 5′-ACAAAGGTA AACCCCGATCC-3′.
Measurement of PKA activity
PKA activity was measured using SignaTECT cAMP-dependent PKA assay (Promega, Southampton, UK), which utilizes biotinylated kemptide (LRRASLG), a peptide substrate derived from the in vivo substrate pyruvate kinase. A10 cells (5 × 10 6 cells) were pre-incubated with control buffer or with the D 4 receptor agonist, PD168077 (10 − 7 mol l − 1 ), for 30 min at 37°C; the cells were washed with ice-cold phosphate-buffered saline once, followed by the complete removal of the buffer. PKA activity was measured by scintillation counting. 17, 25, 26 only 2 groups were compared), and comparison among groups (or t-test when only two groups were compared) was based on one-way factorial ANOVA with Holm-Sidak test. A value of Po0.05 was considered significant.
RESULTS

Stimulation of the D 4 receptor inhibits Ang II-mediated VSMC proliferation and migration
VSMC proliferation and migration have an important role in hypertension and atherosclerosis. To observe the effect of the D 4 receptor on AT 1 receptor function in arteries, we first examined the effects of PD168077, a D 4 receptor agonist, on Ang II-induced proliferation of A10 cells, as determined by MTT uptake and cell counting. Ang II stimulated VSMC proliferation of the A10 cells in a concentration-dependent manner (10 − 8 -10 − 6 mol l − 1 ) ( Figure 1a ). Although PD168077 (10 − 10 -10 − 6 mol l − 1 ), by itself, had no effect on cell proliferation (Figure 1b) , it reduced the Ang II (10 − 7 mol l − 1 per 24 h)-mediated VSMC proliferation in a concentration-dependent manner (10 − 10 -10 − 6 mol l − 1 ) (Figures 1c and d) . The inhibitory effect of the D 4 receptor was specific because in the presence of D 4 We also studied the effects of Ang II and PD168077 on VSMC migration by transwell and scratch-wound migration test. The results showed that Ang II significantly increased VSMC migration. PD168077 alone had no effect, but inhibited the Ang II-mediated VSMC migration (Figures 2a and b) . Consistent with the proliferation study, the inhibitory effect was specific because in the presence of the D 4 receptor antagonist L745870 (10 − 7 mol l − 1 per 24 h), the effect of PD168077 was blocked (Figures 2a and b ).
Knockdown of the D 4 receptor by a D 4 receptor-targeting siRNA inhibits Ang II-mediated VSMC proliferation and migration
To specifically determine the involvement of the D 4 receptor, excluding any D 2 or D 3 receptor involvement, in the Ang II-mediated VSMC proliferation and migration, we studied the effect of Ang II and PD168077 on VSMC proliferation and migration after knockdown of the D 4 receptor by a D 4 receptor-targeting siRNA. As shown in Figures 3a and b , in A10 cells transfected with a D 4 receptor siRNA, the effect of Ang II was enhanced and minimized the PD168077-mediated inhibition of Ang II-induced proliferation and migration, confirming the inhibitory effect of D 4 receptors on Ang II-induced proliferation and migration. The inhibitory effect of D 4 receptor-targeting siRNA on D 4 receptor expression is shown in Supplementary Figure S1 .
Activation of the D 4 receptor decreases AT 1a receptor expression in A10 cells
Ang II increases rat VSMC proliferation and migration primarily through the occupation of the AT 1a receptors subtype. To determine the mechanism underlying the negative regulation of Ang II function by the D 4 receptor, we examined the expression of the AT 1 receptor after treatment with a D 4 receptor agonist. The results showed that PD168077-mediated activation of the D 4 receptor decreased AT 1 receptor expression in a concentration (10 − 10 -10 − 6 mol l − 1 )-and time (4-30 h)-dependent manner (Figures 4a and b ) . The effect of the D 4 receptor on the AT 1 receptor expression was exclusively because of the D 4 receptor itself because pretreating the A10 cells with the D 4 receptor antagonist L745870 (10 − 7 mol l − 1 per 24 h) or with a D 4 receptor-targeting siRNA blocked the effects of PD168077 on AT 1 receptor expression (Figures 4c and d) . To determine whether the D 4 receptor-induced AT 1 receptor downregulation involves regulation of protein stability, A10 cells were pretreated with 100 μM of cycloheximide, stimulated with PD168077 (10 − 7 mol l − 1 ) and harvested at different time points (see Supplementary Material) . Then, AT 1 receptor protein was assayed by immunoblotting. The data indicated that AT 1 protein stability was not affected by treatment with PD168077 in A10 cells (Supplementary Figure S2) .
The relative abundance of AT 1a receptor mRNA was detected by RT-PCR ( Figure 4e ) and real-time qRT-PCR ( Figure 4f ). A10 cells were incubated with PD168077(10 − 7 mol l − 1 per 24 h) with or without L745770 (10 − 7 mol l − 1 per 24 h). The results showed that the activation of the D 4 receptor, by PD168077 (10 − 7 mol l − 1 per 24 h), decreased AT 1a receptor mRNA expression, which was blocked in the presence of L745870, suggesting that the regulation of D 4 receptor on AT 1a receptor occurs at the transcriptional, posttranscriptional and translational levels.
Determination of the signaling pathways involved in the negative D 4 receptor effect on AT 1 receptor expression and function To determine the underlying mechanism of the negative regulation of AT 1 receptor expression by the D 4 receptor, we determined whether Migration and proliferation of VSMC through downregulation of AT 1a recepter C Yu et al there is direct interaction between these two receptors. Although we found co-localization between D 4 and AT 1 receptors (Supplementary Figure S3 ), there was no co-immunoprecipitation (data not shown).
We have previously shown that PKA is involved in the negative regulation of insulin receptor expression and function by the D 3 receptor. 17 The negative regulation of AT 1 receptor function by the D 4 receptor, being one of the subtypes of the D 2 -like receptor subfamily, may also involve PKA. We initially determined the activity of PKA in VSMCs after treatment with PD168077. We found that PD168077 increased PKA activity in A10 cells (Figure 5a ). Activation of the D 4 receptor (PD168077, 10 − 7 mol l − 1 ) inhibited AT 1 receptor expression. However, in the presence of the PKA inhibitor (PKA inhibitor 14-22, 10 − 7 mol l − 1 per 24 h), the inhibitory effect of the D 4 receptor on AT 1 receptor expression was blocked (Figure 5b) . To determine the role of PKA in the inhibitory effect of the D 4 receptor on AT 1 receptor function, we assessed the proliferation and migration of A10 cells using the MTT and transwell assays. Consistent with previous studies, stimulation with Ang II increased the proliferation and migration of A10 cells. Ang II-induced proliferation and migration of VSMCs were significantly suppressed by the D 4 receptor agonist, PD168077. Pre-treatment with the PKA inhibitor (PKAI, 10 − 7 mol l − 1 ) or D 4 receptor antagonist, L745870 (10 − 7 mol l − 1 ), blocked the inhibitory effects of PD168077 on Ang II-mediated VSMC proliferation and migration (Figures 5c and d) . These results suggested that the PKA signaling pathway could be responsible for the D 4 receptor-mediated negative regulation of AT 1 receptor expression and function in VSMCs.
Effect of the D 4 receptor on AT 1 receptor-mediated proliferation and migration in aortic VSMCs from WKY and SHRs
To determine whether the inhibition of the D 4 receptor on AT 1 receptor-mediated proliferation and migration of VSMCs had any physiological significance in hypertension, we compared the proliferative and migratory capacities of An II in primary cultures of aortic VSMCs from SHRs and WKY rats. The basal levels of proliferation were higher in VSMCs from SHRs than those from WKY rats, although Ang II significantly induced greater MTT uptake and a higher rate of migration in VSMCs from both SHRs and WKY rats (Figures 6a and b) . PD168077 significantly attenuated the stimulatory effect of Ang II on VSMC proliferation (WKY:32.1 ± 4.3% vs SHR:29.1 ± 3.6%) and migration (WKY:46.0 ± 6.4% vs SHR:39.4 ± 6.9%) in both SHRs and WKY rats. The inhibitory effect of PD168077 did not show any significant difference between the strains. Additionally, we evaluated the expression of the AT 1 receptor in VSMCs from SHR and WKY rats after treatment with PD168077 (10 − 7 mol l − 1 for 24 h). As shown in Figure 6c , the basal level of AT 1 receptor expression was significantly higher in VSMCs from SHRs than those from WKY rats. However, the D 4 receptor significantly inhibited AT 1 receptor expression in VSMCs from both SHRs and WKY rats. No difference was observed in the degree of inhibition of AT 1 receptor expression by the D 4 receptor between SHR and WKY cells (SHR:46.8 ± 1.96% vs WKY:44.9 ± 1.2%). These results indicated that the inhibitory effect of the D 4 receptor in arteries is preserved in hypertension; therefore, the D 4 receptor could be a possible target for reduction of VSMC proliferation and migration in hypertension and atherosclerosis.
DISCUSSION
Ang II contributes to vascular lesions by promoting VSMC proliferation and migration. However, the mechanism remains to be defined. Multiple pieces of evidence strongly implicate the action of Ang II through the AT 1a receptor, as the mediator of VSMC proliferation and migration that are important in the development of atherosclerosis and hypertension. Thus, the inhibition of VSMC proliferation or migration may potentially be an important therapeutic strategy for the treatment of hypertension. 6, 24, [27] [28] [29] Several studies have shown that the dopamine and AT 1 receptors interact to regulate sodium and water balance in the kidney. [13] [14] [15] 30 AT 1 receptors stimulate renal proximal tubular ion-transporting proteins that are inhibited by D 1 -like receptors and therefore, the natriuretic effect of D 1 -like receptors is enhanced when AT 1 receptors are blocked. 13 The D 1 -like receptor agonist fenoldopam decreases AT 1 receptor expression in renal proximal tubule cells from WKY rats and SHRs. 13 Increases in [Na + ]i led to a higher number of D 1 receptors in the plasma membrane that is paralleled by a reduced abundance of AT 1 receptors in the opossum kidney (OK) epithelial cell line. 30 Exposure of rat renal proximal tubule cells to a D 1 receptor agonist resulted in a rapid partial internalization of the AT 1 receptor and complete inhibition of AT 1 receptor signaling. 13 
D 3
− / − mice have renin-dependent hypertension and renal AT 1 receptor function is greater in D 3 − / − mice than their wild-type (D 3 +/+ ) littermates. 31 Activation of the D 3 receptor decreases AT 1 receptor expression in renal proximal tubule cells from normotensive rats. 15 The protein expression of the AT 1 receptor is also increased in homogenates of the kidney of D 4 − / − mice relative to their D 4 +/+ littermates. 12 However, whether there is an interaction between D 4 and AT 1 receptors in resistance arteries has not been reported. We now report an interaction between D 4 and AT 1a receptors in A10 cells. The stimulation of D 4 receptors decreased AT 1a receptor mRNA and protein expression but did alter AT 1 receptor protein stability. Therefore, the D 4 receptormediated negative regulation of AT 1a receptor expression may be exerted at the transcriptional, post-transcriptional and translational levels. However, the potential mechanisms by which the D 4 receptor downregulates AT 1a receptor gene transcription or AT 1a receptor mRNA stability remain to be investigated.
Previous studies have shown that stimulation of the D 4 or D 3 receptor inhibits insulin-mediated VSMC proliferation. 16, 17 The D 4 receptor decreases the expression of AT 1 receptors in VSMCs. However, whether the D 4 receptor has an inhibitory effect on Ang II-mediated VSMC proliferation and migration is not known. In this report, we showed that activation of the D 4 receptor inhibited the proliferation and migration of VSMCs that were induced by Ang II, although stimulation of the D 4 receptor by itself had no effect. Transfection of VSMCs with D 4 receptor-targeting siRNA almost completely prevented the inhibitory effect of D 4 receptor activation by PD168077 on Ang II-induced proliferation and migration. This result, together with the ability of a D 4 receptor antagonist to minimize also the effect of a D 4 receptor agonist, confirmed that the D 4 receptor can antagonize the ability of Ang II to induce VSMC proliferation and migration.
Our previous study showed that PKA is involved in the negative regulation of VSMC insulin receptor expression by the D 3 receptor, 17 another subtype in the D 2 -like receptor subfamily. Therefore, we sought to determine whether PKA is similarly involved in the negative regulation of the AT 1 receptor by the D 4 receptor. In the current study, we found that PKA activity in VSMCs was increased after treatment with the D 4 receptor agonist PD168077. A PKA inhibitor prevented the inhibitory effect of the D 4 receptor on AT 1 receptor protein expression as well as the VSMC proliferation and migration mediated by Ang II, which suggested that the PKA signaling pathway is involved in the regulation of D 4 receptor on AT 1 receptor expression and function. Although, D 2 -like receptors are generally associated with inhibition of the PKA pathway, under certain circumstances, in some cells, D 2 -like receptors stimulate adenylyl cyclase activity. [32] [33] [34] Dopamine receptor function, especially that of the D 1 and D 3 receptors, is impaired in the kidneys from hypertensive patients and SHRs, 31, 35, 36 whereas their effects are preserved in arteries. Our previous study showed that activation of the D 1 or D 3 receptor inhibits alpha1-adrenergic receptor-mediated proliferation in VSMCs. 37 The current study also found that the inhibitory effects of the D 4 receptor on AT 1 receptor expression and function are preserved in primary culture of VSMCs from WKY and SHRs. Figure 5 Role of protein kinase A in the inhibitory effect of PD168077 on AT 1 receptor expression and function in A10 cells. A10 cells were treated with a D 4 receptor agonist (PD168077, 10 − 7 mol l − 1 ), a D 4 receptor antagonist (L, L745870, 10 − 7 mol l − 1 ) or both D 4 receptor agonist (PD) and D 4 receptor antagonist (L, L745870, 10 − 7 mol l − 1 ) for 24 h. The activity of protein kinase A was determined by cAMP-dependent protein kinase A assay (a, n = 6, *Po0.05 vs others). The inhibitory effect of D 4 receptor agonist, PD168077 (PD, 10 − 7 mol l − 1 ) on AT 1 receptor expression was blocked in the presence of protein kinase A inhibitor 14-22 (PKAI, 10 − 7 mol l − 1 ). The immunoblotting density was normalized by α-actin density (b, n = 6, *Po0.05 vs others). The inhibitory effect of a D 4 receptor agonist, PD168077 (PD, 10 − 7 mol l − 1 ), on Ang II (10 − 7 mol l − 1 )-mediated vascular smooth muscle cell proliferation and migration was abolished in the presence of PKA inhibitor 14-22 (PKAI, 10 − 7 mol l − 1 ). Vascular smooth muscle cell proliferation was determined by the uptake of 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (c, n = 5, *Po0.05 vs control; # Po0.05 vs Ang II alone). Vascular smooth muscle cell migration was determined by transwell assay (d, n = 5, *Po0.05 vs control; # Po0.05 vs Ang II alone).
In conclusion, our data provide insight into the negative regulation of AT 1a receptor expression and function by the D 4 receptor in VSMCs and suggest that targeting the action of the D 4 receptor may represent an effective therapeutic approach in the treatment of cardiovascular diseases. Figure 6 Effect of the D 4 receptor on AT 1 receptor expression and function in vascular smooth muscle cells from Wistar-Kyoto rats and spontaneously hypertensive rats: the effect of PD168077 on the proliferation and migration of vascular smooth muscle cells from Wistar-Kyoto rats and spontaneously hypertensive rats in response to Ang II. The primary cultured vascular smooth muscle cells from Wistar-Kyoto rats and spontaneously hypertensive rats were stimulated with vehicle (control), Ang II (10 − 7 mol l − 1 ), D 4 receptor agonist (PD168077, 10 − 7 mol/l), or Ang II (10 − 7 mol l − 1 ) for 24 h. The proliferation of vascular smooth muscle cells was measured by the uptake of 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (a, n = 6, *Po0.05 vs control; # Po0.05 vs Ang II alone). Vascular smooth muscle cells migration was measured by transwell assay (b, n = 6, *Po0.05 vs control; # Po0.05 vs Ang II alone). The effect of PD168077 on AT 1 expression in vascular smooth muscle cells from Wistar-Kyoto rats and spontaneously hypertensive rats was quantified by immunoblotting (c, n = 6, *Po0.05 vs control; # Po0.05 vs Wistar-Kyoto control).
